AXIM Biotechnologies, Inc.
AXIM · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.32 | 0.01 | -0.03 |
| FCF Yield | -141.59% | -23.82% | -44.79% | -4.45% |
| EV / EBITDA | -2.96 | -1.57 | -2.59 | -4.80 |
| Quality | ||||
| ROIC | 54.46% | 156.12% | -554.34% | -180.91% |
| Gross Margin | -524.10% | 100.00% | -4,701.42% | 100.00% |
| Cash Conversion Ratio | 0.24 | 0.13 | 0.33 | 0.16 |
| Growth | ||||
| Revenue 3-Year CAGR | 99.49% | -13.22% | – | -57.71% |
| Free Cash Flow Growth | 16.75% | 49.81% | 19.08% | 23.42% |
| Safety | ||||
| Net Debt / EBITDA | -2.72 | -0.89 | -1.43 | -0.48 |
| Interest Coverage | -2.77 | -2.28 | -2.48 | -10.74 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,482.43 | 0.00 | -1,127.44 | 0.00 |